



Dr. R. Michael Tuttle, an Endocrinologist, Professor of Medicine, and Chief of the Endocrinology Service at Memorial Sloan Kettering Cancer Center in New York, designed and validated the first real time risk assessment model for thyroid cancer management in which individual risk estimates are modified over time as a function of response to initial therapy. His research

continues to center on important management aspects of thyroid cancer including efforts to better define (1) the risk of recurrence and death from thyroid cancer for individual patients, (2) the role of active surveillance in properly selected patients with low-risk papillary thyroid cancer, and (3) the proper application of minimalistic management options to better tailor the intensity of therapy and follow-up to the risks of undesirable outcomes. His clinical practice is entirely devoted to the evaluation and management of patients with thyroid cancer.